<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="641">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01998841</url>
  </required_header>
  <id_info>
    <org_study_id>GN28352</org_study_id>
    <nct_id>NCT01998841</nct_id>
  </id_info>
  <brief_title>A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Banner Alzheimer's Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This study consists of 2 periods: [1] Study Period A - evaluating the efficacy and safety of&#xD;
      Crenezumab versus Placebo in participants who carry the PSEN1 E280A autosomal-dominant&#xD;
      mutation and do not meet the criteria for mild cognitive impairment due to AD or dementia due&#xD;
      to AD and are thus, in a preclinical phase of AD. Participants will be randomised in a 1:1&#xD;
      ratio to receive either Crenezumab or Placebo subcutaneously (every 2 weeks) or intravenously&#xD;
      (every 4 weeks) for at least 260 weeks. A cohort of participants (non-mutation carriers) will&#xD;
      also be enrolled and will be dosed solely on Placebo and [2] Study Period B - Participants&#xD;
      will be offered the opportunity to continue to receive study drug until the results of the&#xD;
      study are known and post trial access to Crenezumab is started or development of Crenezumab&#xD;
      is discontinued.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 20, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annualized rate of change on the Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease (API ADAD) Composite Cognitive Test Total Score</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized rate of change in an Episodic Memory Measure: Free and Cued Selective Reminding Task (FCSRT)</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression from preclinical AD to Mild Cognitive Impairment (MCI) due to AD or from preclinical AD to dementia due to AD</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Clinical Dementia Rating (CDR) Scale Global Score of Greater Than (&gt;) Zero</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in the CDR Scale - Sum of Boxes</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in a Measure of Overall Neurocognitive Functioning: Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in Mean Cerebral Fibrillar Amyloid Accumulation Standard Uptake Value Ratio (SUVR) as Assessed by Positron Emission Tomography (PET)</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in Regional Cerebral Metabolic Rate of Glucose (CMRgI) Using Fluorine-18-Labeled 2-Deoxyglucose (FDG)-PET</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in Brain Atrophy Measured by Volumetric Measurements Using Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of change in a tau-Based Cerebral Spinal Fluid (CSF) Biomarker</measure>
    <time_frame>Baseline to at least Week 260 (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 up to 16 weeks following the last administration of study drug or study discontinuation/termination, whichever is later (up to approximately 432 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-Crenezumab Antibodies</measure>
    <time_frame>Day 1 up to 16 weeks following the last administration of study drug or study discontinuation/termination, whichever is later (up to approximately 432 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CSF Crenezumab Concentration</measure>
    <time_frame>Baseline (at least 72 hours prior to the first study drug administration); Weeks 104 and 260; at study completion/early discontinuation (up to approximately 416 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Crenezumab Concentration</measure>
    <time_frame>Predose (Hour 0) at Baseline, Weeks 4, 12, 16, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, 260, 284, 312, 336, 364, 388, 416, and 16 weeks after last dose/early discontinuation (up to approximately 432 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">252</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Mutation Carriers: Crenezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study Period A: Participants will receive Crenezumab subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.&#xD;
Study Period B: Participants will be offered the opportunity to continue to receive blinded study drug until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mutation Carriers: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.&#xD;
Study Period B: All mutation carriers entering Study Period B will, receive Crenezumab until the results of the study are known and post-trial access to Crenezumab is started or development of Crenezumab is discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-carriers of Mutation: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study Period A: Participants will receive Placebo subcutaneously (every 2 weeks) or intravenously (every 4 weeks) for at least 260 weeks.&#xD;
Study Period B: All non-mutation carriers entering Study Period B will continue to receive Placebo, until the results of the study are known and post trial access to Crenezumab is started or development of Crenezumab is discontinued.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crenezumab</intervention_name>
    <description>Crenezumab will be administered as per the schedule specified in the treatment arm.</description>
    <arm_group_label>Mutation Carriers: Crenezumab</arm_group_label>
    <other_name>MABT5102A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as per the schedule specified in the treatment arm.</description>
    <arm_group_label>Mutation Carriers: Placebo</arm_group_label>
    <arm_group_label>Non-carriers of Mutation: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Membership in PSEN1 E280A mutation carrier kindred&#xD;
&#xD;
          -  Agrees to conditions of, and is willing to undergo, genetic testing (for example&#xD;
             [e.g.], apolipoprotein E [APOE], PSEN1 E280A, and other genetic testing)&#xD;
&#xD;
          -  PSEN1 E280A mutation carrier or non-carrier status has been confirmed prior to or&#xD;
             during the screening period&#xD;
&#xD;
          -  Mini-Mental Stage Examination (MMSE) greater than or equal to (&gt;=) 24 for participants&#xD;
             with less than (&lt;) 9 years of education or MMSE &gt;=26 for participants with 9 or more&#xD;
             years of education&#xD;
&#xD;
          -  Does not meet criteria for dementia due to AD per the National Institute on Aging and&#xD;
             the Alzheimer's Association Workgroup (McKhann et al. 2011) criteria&#xD;
&#xD;
          -  Does not meet criteria for mild cognitive impairment (MCI) due to AD per the National&#xD;
             Institute on Aging and the Alzheimer's Association Workgroup (Albert et al. 2011)&#xD;
             criteria&#xD;
&#xD;
          -  Adequate vision and hearing in the investigator's judgment to be able to complete&#xD;
             testing&#xD;
&#xD;
          -  If female, and not documented (by medical records or physician's note) to be&#xD;
             surgically sterile (absence of ovaries and/or uterus) or postmenopausal, willing to&#xD;
             undergo pregnancy tests at protocol-specific timepoints&#xD;
&#xD;
          -  For women who are not documented (by medical records or physician's note) to be&#xD;
             surgically sterile (absence of ovaries and/or uterus) or postmenopausal, agreement to&#xD;
             remain abstinent or use two adequate methods of contraception, including at least one&#xD;
             method with a failure rate of &lt;1 percent (%) per year (e.g., hormonal implants,&#xD;
             combined oral contraceptives, vasectomized partner, tubal ligation) during the&#xD;
             treatment period and for at least 16 weeks after the last dose of study drug&#xD;
&#xD;
          -  For men with partners of childbearing potential (that is [i.e.], women who are not&#xD;
             surgically sterile and are not postmenopausal), agreement to remain abstinent or use a&#xD;
             condom as a method of contraception during the treatment period and for at least 8&#xD;
             weeks after the last dose of study drug&#xD;
&#xD;
          -  Study partner who agrees to participate in the study and is capable of and willing to:&#xD;
             accompany the participant to all required visits; provide information for required&#xD;
             telephone assessments; spend sufficient time with the participant to be familiar with&#xD;
             his/her overall function and behavior and be able to provide adequate information&#xD;
             about the participant including knowledge about domestic activities, hobbies,&#xD;
             routines, social skills and basic activities of daily life; work and educational&#xD;
             history; cognitive performance including memory abilities, language abilities,&#xD;
             temporal and spatial orientation, judgment and problem solving; emotional and&#xD;
             psychological state; and general health status&#xD;
&#xD;
          -  Participant and study partner have evidence of adequate premorbid functioning (e.g.,&#xD;
             intellectual, visual, and auditory) and are fluent in, and able to read, the language&#xD;
             in which study assessments are administered&#xD;
&#xD;
          -  Willing and able to undergo neuroimaging (PET and MRI)&#xD;
&#xD;
          -  Serum thyroid stimulating hormone (TSH) and B12 levels within normal or expected&#xD;
             ranges for the testing laboratory or if TSH and B12 values are out of range they are&#xD;
             judged by the investigator not to be clinically significant. If participant is&#xD;
             undergoing thyroid replacement therapy, TSH levels must be within normal or expected&#xD;
             ranges for the testing laboratory or, if TSH values are out of range, they do not&#xD;
             require any therapeutic actions (treatment or surveillance). If participant is&#xD;
             receiving vitamin B12 injections or oral vitamin B12 therapy, B12 levels must be at or&#xD;
             above the lower limit of normal for the testing laboratory or, if B12 values are out&#xD;
             of range, they do not require any therapeutic actions (treatment or surveillance)&#xD;
&#xD;
          -  In good general health with no known co-morbidities expected to interfere with&#xD;
             participation in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant medical, psychiatric, or neurological condition or disorder documented by&#xD;
             history, physical, neurological, laboratory, or electrocardiogram (ECG) examination&#xD;
             that would place the participant at undue risk in the investigator's judgment or&#xD;
             impact the interpretation of efficacy&#xD;
&#xD;
          -  History of stroke. Participants with a history of transient ischemic attack may be&#xD;
             enrolled if the event occurred &gt;=2 years prior to screening&#xD;
&#xD;
          -  History of severe, clinically significant (persistent neurological deficit or&#xD;
             structural brain damage) central nervous system trauma (e.g. cerebral contusion)&#xD;
&#xD;
          -  Body weight &lt;45 or &gt;120 kilograms (kg)&#xD;
&#xD;
          -  History or presence of atrial fibrillation that poses a risk for future stroke in the&#xD;
             investigator's judgment&#xD;
&#xD;
          -  Clinically significant laboratory or ECG abnormalities (e.g., abnormally prolonged or&#xD;
             shortened QTc interval) in the investigator's judgment&#xD;
&#xD;
          -  Current presence of bipolar disorder or other clinically significant major psychiatric&#xD;
             disorder according to Diagnostic and Statistical Manual of Mental Disorders 4th&#xD;
             Edition Text Revision (DSM-IV-TR) or symptom (e.g., hallucinations, agitation,&#xD;
             paranoia) that could affect the participant's ability to complete evaluations&#xD;
&#xD;
          -  Clinically significant depression, based in part by a Geriatric Depression Scale&#xD;
             (short form) (15-point scale) score &gt;9 at screening&#xD;
&#xD;
          -  History of seizures (excluding febrile seizures of childhood, or other isolated&#xD;
             seizure episodes that were not due to epilepsy in the judgment of the investigator,&#xD;
             and required at most time-limited anticonvulsant treatment, and which occurred more&#xD;
             than 7 years prior to the screening visit)&#xD;
&#xD;
          -  Myocardial infarction within 2 years, congestive heart failure, atrial fibrillation,&#xD;
             or uncontrolled hypertension&#xD;
&#xD;
          -  Pregnant or nursing women, or women who intend to become pregnant or to nurse infants&#xD;
             during the conduct of this trial&#xD;
&#xD;
          -  Clinically significant infection within the last 30 days prior to screening&#xD;
&#xD;
          -  Positive urine test for drugs of abuse at screening&#xD;
&#xD;
          -  History of alcohol or substance dependence within the previous two years&#xD;
&#xD;
          -  Use of any other medications with the potential to significantly affect cognition;&#xD;
             intermittent or short-term use of these medications may be allowed if deemed medically&#xD;
             necessary for the treatment of a non-excluded medical condition with approval from the&#xD;
             Medical Monitor. In addition, use of tricyclic antidepressants or benzodiazepines will&#xD;
             be permitted if used in stable, low doses for the treatment of a non-excluded medical&#xD;
             condition with approval from the Medical Monitor&#xD;
&#xD;
          -  Use of typical anti-psychotics or barbiturates&#xD;
&#xD;
          -  Use of non-anti-cholinergic antidepressant medications or atypical anti-psychotics&#xD;
             unless maintained on a stable dose regimen for at least 6 weeks prior to screening&#xD;
&#xD;
          -  Use of any Food and Drug Administration (FDA)/Instituto Nacional de Vigilancia de&#xD;
             Medicamentos y Alimentos (INVIMA)-approved medications for treatment of late onset&#xD;
             Alzheimer's disease (LOAD) at screening/baseline. Cholinesterase inhibitors and/or&#xD;
             memantine are prohibited during the study except in participants enrolled in the study&#xD;
             that develop AD dementia&#xD;
&#xD;
          -  Use of anti-coagulant medication (heparinoids, heparin, warfarin, thrombin inhibitors,&#xD;
             Factor Xa inhibitors), or known coagulopathy or platelet count &lt;100,000&#xD;
             cells/microliter, within 4 weeks of the screening visit; Anti-platelet medications&#xD;
             (e.g., aspirin, clopidigrel, dipyridamole) are permitted if on a stable dose for 4 or&#xD;
             more weeks prior to screening. Short-term, peri-operative use of anti-coagulants may&#xD;
             not result in discontinuation from the study; however, any such use must be discussed&#xD;
             with the Medical Monitor&#xD;
&#xD;
          -  Treatment with any biologic therapy within five half-lives or 3 months prior to&#xD;
             screening, whichever is longer, with the exception of routinely recommended&#xD;
             vaccinations, which are allowed&#xD;
&#xD;
          -  Use of anti-seizure medication (except in childhood for febrile seizures or if used&#xD;
             for non-seizure indications), anti-parkinsonian, or stimulant (e.g., methylphenidate)&#xD;
             medications&#xD;
&#xD;
          -  Use of investigational drug, device, or experimental medication within 60 days (or&#xD;
             five half-lives, whichever is longer) of the screening visit&#xD;
&#xD;
          -  Previous treatment with crenezumab or any other therapeutic that targets A-beta&#xD;
&#xD;
          -  History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric, human, or humanized antibodies or fusion proteins&#xD;
&#xD;
          -  Contraindication to MRI scan procedures or clinically significant claustrophobia that&#xD;
             would contraindicate a brain MRI scan&#xD;
&#xD;
          -  Contraindication to PET scan procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion Cardiomet</name>
      <address>
        <city>Armenia</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cl√≠nica de Marly</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grupo Neurociencias de Antioquia</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Yarumal</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>November 22, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2013</study_first_posted>
  <last_update_submitted>March 7, 2022</last_update_submitted>
  <last_update_submitted_qc>March 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

